Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment

Eric W Pefura Yone1 Department of Internal Medicine and Subspecialties, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Cameroon;2 Approved Centre for HIV Treatment and Pneumology Service, Yaounde Jamot Hospital, CameroonCorrespondence[email protected]

André P Kengne3 South African Medical Research Council and University of Cape Town, Cape Town, South Africa

Pages 181-184 | Published online: 05 Dec 2012

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

EggerMMayMCheneGPrognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studiesLancet200236011912912126821
PubMed Web of Science ®Google Scholar
PalellaFJJrDelaneyKMMoormanACDeclining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study InvestigatorsN Engl J Med19983388538609516219
PubMed Web of Science ®Google Scholar
Organisation Mondiale de la SantéRecommandations rapides: Traitement antirétroviral de l’infection à VIH chez l’adulte et l’adolescent2010 Available from: http://www.who.int/hiv/pub/arv/rapid_advice_art_fr.pdfAccessed December 12, 2011
Google Scholar
ThompsonMAAbergJACahnPAntiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panelJAMA201030432133320639566
PubMed Web of Science ®Google Scholar
ThompsonMAAbergJAHoyJFAntiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panelJAMA201230838740222820792
PubMed Web of Science ®Google Scholar
HeilELCorbettAHGuidelines for the use of extended-release nevirapine in HIV-infected patientsExp Opin Pharmacother20111227132718
Web of Science ®Google Scholar
Boehringer Ingelheim Pharmaceuticals IncMonographie de VIRAMUNE2011 Available from: http://www.boehringer-ingelheim.ca/content/dam/internet/opu/ca_FR/documents/monographie/VIRAMUNE_pm_fr.pdfAccessed September 12, 2012
Google Scholar
ClotetBOnce-daily dosing of nevirapine in HAARTJ Antimicrob Chemother200861131618006524
PubMed Web of Science ®Google Scholar
ReyDHoenBChavanetPHigh rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patientsJ Antimicrob Chemother20096338038819036752
PubMed Web of Science ®Google Scholar
SwaminathanSPadmapriyadarsiniCVenkatesanPEfficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trialClin Infect Dis20115371672421890776
PubMed Web of Science ®Google Scholar
WeberschockTGholamPHueterEFluxKHartmannMLong-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: A 72-week prospective multicenter study (TENOR-Trial)Eur J Med Res20091451651920149984
PubMed Web of Science ®Google Scholar
Boehringer Ingelheim Pharmaceuticals IncViramune XR prescribing information2011 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201152s000lbl.pdfAccessed September 12, 2012
Google Scholar
DellamonicaPDi PerriGGarraffoRNNRTIs: Pharmacological dataMed Mal Infect20124228729522727649
PubMed Web of Science ®Google Scholar
Sluis-CremerNTachedjianGMechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitorsVirus Res200813414715618372072
PubMed Web of Science ®Google Scholar
BattegayMArastehKPlettenbergABioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label studyClin Ther2011331308132021872931
PubMed Web of Science ®Google Scholar
GatheJAndrade-VillanuevaJSantiagoSEfficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patientsAntivir Ther20111675976921817198
PubMed Web of Science ®Google Scholar
ArastehKWardDPlettenbergATwenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION)HIV Med20121323624422136068
PubMed Web of Science ®Google Scholar
BoyleBAJayaweeraDWittMDGrimmKMaaJFSeekinsDWRandomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppressionHIV Clin Trials2008916417618547903
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date